{
    "clinical_study": {
        "@rank": "141084", 
        "arm_group": [
            {
                "arm_group_label": "NNC0195-0092", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Norditropin NordiFlex\u00ae", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the safety,\n      tolerability, availability and distribution in the body of once-weekly long-acting growth\n      hormone (NNC0195-0092) compared to once daily Norditropin NordiFlex\u00ae in adults with growth\n      hormone deficiency (GHD)."
        }, 
        "brief_title": "A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone Compared to Once Daily Norditropin NordiFlex\u00ae in Adults With Growth Hormone Deficiency", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Growth Hormone Disorder", 
            "Adult Growth Hormone Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults with GHD as defined in the consensus guidelines for the diagnosis and\n             treatment of adults with GHD\n\n          -  Stable human growth hormone (hGH) replacement therapy for at least 3 months\n\n        Exclusion Criteria:\n\n          -  Participation in another clinical trial within 3 months or receipt of any\n             investigational medicinal product within 3 months prior to randomisation\n\n          -  Active malignant disease or malignant disease within the last 5 years with exception\n             of fully treated local basal cell carcinoma or carcinoma in situ of cervix\n\n          -  Proliferative retinopathy judged by retina-photo within the last year - only with\n             concomitant diabetes\n\n          -  Heart insufficiency, New York Heart Association (NYHA) class above 2\n\n          -  Adults with GHD with poorly controlled diabetes mellitus with a glycosylated\n             haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment\n\n          -  Stable pituitary replacement therapy for less than 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706783", 
            "org_study_id": "NN8640-3947", 
            "secondary_id": [
                "2011-005484-24", 
                "U1111-1125-7331"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "NNC0195-0092", 
                "description": "Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 in an escalating order", 
                "intervention_name": "NNC0195-0092", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Norditropin NordiFlex\u00ae", 
                "description": "Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency", 
                "intervention_name": "Norditropin NordiFlex\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 26, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "K\u00f8benhavn \u00d8", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "141 86"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Open-labelled, Active-controlled, Multiple Dose, Dose Escalating, Sequential Dose Group Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-weekly Long-acting Growth Hormone (NNC0195-0092) Compared to Once-daily Norditropin NordiFlex\u00ae in Adults With Growth Hormone Deficiency", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Lene Finnerup Nielsen", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "From first administration of trial product and up until Day 49"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706783"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "NNC0195-0092 only: Area under the curve, AUC (0-168h)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }, 
            {
                "measure": "Norditropin NordiFlex\u00ae only: AUC (0-24h)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 24 hours"
            }, 
            {
                "measure": "NNC0195-0092, first dose administration only: AUC (0-168h)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }, 
            {
                "measure": "Norditropin NordiFlex\u00ae, first dose administration only: AUC (0-24h)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 24 hours"
            }, 
            {
                "measure": "NNC0195-0092: Maximum serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }, 
            {
                "measure": "Norditropin NordiFlex\u00ae: Cmax", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 24 hours"
            }, 
            {
                "measure": "Insulin-like growth factor I (IGF-I): AUC (0-168h)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }, 
            {
                "measure": "IGF-I: Cmax", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }, 
            {
                "measure": "Insulin-like growth factor binding protein-3 (IGFBP-3): AUC IGFBP-3(0-168h)", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }, 
            {
                "measure": "IGFBP-3: Cmax", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 168 hours"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}